Company profile: Arcellx
1.1 - Company Overview
Company description
- Provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Products and services
- ACLX-001: A controllable, bivalent ARC-T cell therapy utilizing a SparX protein that targets BCMA, delivering BCMA-directed activity in relapsed or refractory multiple myeloma
- ACLX-002: An ARC-SparX platform cell therapy using a SparX protein to target CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
- Anitocabtagene autoleucel: A CAR-T cell therapy targeting BCMA for treatment of relapsed or refractory multiple myeloma, currently in a Phase 1 study.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arcellx
Tectonic Therapeutics
HQ: United States
Website
- Description: Provider of GPCR-targeted biologic drug discovery and development via its GEODe platform, with clinical programs including TX45, a therapeutic protein in Phase 1B trials for Group 2 Pulmonary Hypertension in heart failure with preserved ejection fraction, and an Fc-relaxin fusion targeting the RXFP1 receptor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tectonic Therapeutics company profile →
Corvus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corvus Pharmaceuticals company profile →
Vical
HQ: United States
Website
- Description: Provider of biopharmaceutical product research and development based on its patented DNA delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vical company profile →
InDex Pharmaceuticals
HQ: Sweden
Website
- Description: Provider of clinical-stage biopharmaceutical immunotherapy R&D based on a toll-like receptor (TLR) platform, discovering and developing DNA-based immunomodulatory sequence (DIMS) drugs to treat diseases in therapeutic areas including inflammation and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InDex Pharmaceuticals company profile →
Takara Bio
HQ: Japan
Website
- Description: Provider of life science reagents, kits, gene therapy solutions, and contract biology development services. Develops, manufactures, and distributes products under the Takara, Clontech, and Cellartis brands, including SMART cDNA synthesis kits for NGS and other applications, and high-performance qPCR/PCR reagents such as Takara Ex Taq and Takara LA Taq.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Takara Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arcellx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arcellx
2.2 - Growth funds investing in similar companies to Arcellx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arcellx
4.2 - Public trading comparable groups for Arcellx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →